



Fig. S1. (a) Evolution of the basophil FcεRI receptor expression and (b) evolution of 7-day Urticaria Activity Score (UAS7) and Urticaria Control Test (UCT) in the total of patients with CSU ($n=47$) during omalizumab therapy (levels of FcεRI receptor and UAS7 are expressed as percentage of decrease from baseline, while values of UCT are expressed as percentage of increase from baseline).